Age, y |
<65 |
8 |
9023 |
−17.06 (−31.04, −3.08) I2=0, Z=2.39 (P=0.02) |
−18.39 (−34.87, −1.91) I2=0, Z=2.19 (P=0.03) |
−3.30 (−6.78, 0.18)*, Z=1.86 (P=0.06) |
−2.48 (−3.77, −1.18) I2=0, Z=3.74 (P=0.0002) |
−6.59 (−11.23, −1.95) I2=0, Z=2.78 (P=0.005) |
−7.32 (−14.35, −0.28) I2=0, Z=2.04 (P=0.04) |
−474.47 (−538.92, −410.02) I2=0, Z=14.43 (P<0.00001) |
−2.35 (−2.87, −1.83) I2=0, Z=8.86 (P<0.00001) |
≥65 |
9 |
988 |
−5.52 (−8.42, −2.63) I2=40%, Z=3.73 (P=0.0002) |
−18.07 (−20.50, −15.64) I2=87%, Z=14.60 (P<0.00001) |
−3.40 (−6.54, −0.26)*, Z=2.12 (P=0.03) |
−2.42 (−3.17, −1.67) I2=0, Z=6.35 (P<0.00001) |
−4.35 (−7.93, −0.77)I2=73%, Z=2.38 (P=0.02) |
−3.86 (−8.2, 0.48) I2=0, Z=1.75 (P=0.08) |
−228.49 (−257.90, −199.09) I2=91%, Z=15.23 (P<0.00001) |
−1.98 (−5.03, 1.08) I2=0, Z=1.27 (P=0.2) |
Region |
Europe |
14 |
1226 |
−17.47 (−29.12, −5.82) I2=0, Z=2.94 (P=0.003) |
−21.58 (−24.34, −18.83) I2=16%, Z=15.34 (P<0.00001) |
NR |
−2.41 (−3.21, −1.61) I2=0, Z=5.91 (P<0.00001) |
NR |
−6.72 (−13.94, 0.5)*, Z=1.82 (P=0.07) |
−228.49 (−257.90, −199.09) I2=91%, Z=15.23 (P<0.00001) |
−5.52 (−12.16, 1.12) I2=0, Z=1.63 (P=0.1) |
North America |
3 |
131 |
−21.87 (−44.39, 0.66) I2=0, Z=1.90 (P=0.06) |
−22.17 (−47.37, 3.03) I2=0, Z=1.72 (P=0.08) |
−3.60 (−6.16, −1.05) I2=0, Z=2.77 (P=0.006) |
−2.48 (−3.63, −1.34) I2=0, Z=4.25 (P<0.0001) |
NR |
−9 (−25.07, 7.07)*, Z=1.1 (P=0.27) |
NR |
NR |
Asia |
1 |
118 |
−17.7 (−36.15, 0.75)*, Z=1.88 (P=0.06) |
−22 (−44.25, 0.25)*, Z=1.94 (P=0.05) |
−3.30 (−6.78, 0.18)*, Z=1.86 (P=0.06) |
−2.20 (−5.04, 0.64)*, Z=1.52 (P=0.13) |
NR |
−18.30 (−49.32, 12.72)*, Z=1.16 (P=0.25) |
NR |
NR |
Global multiple centers |
2 |
8700 |
−6.9 (−11.35, −2.45)*, Z=3.04 (P=0.002) |
−10.4 (−17.86, −2.94)*, Z=2.73 (P=0.006) |
NR |
NR |
NR |
NR |
−305.95 (−346.51, −265.38) I2=94%, Z=14.78 (P<0.00001) |
−2.46 (−3.19, −1.74) I2=0, Z=6.64 (P<0.00001) |
Follow‐up |
Intervention effect ≤6 mo |
13 |
1009 |
−5.25 (−8.97, −1.53) I2=45%, Z=2.77 (P=0.006) |
−18.97 (−21.51, −16.43) I2=82%, Z=14.63 (P<0.00001) |
−3.60 (−6.16, −1.05) I2=0, Z=2.77 (P=0.006) |
−2.43 (−3.09, −1.78) I2=0, Z=7.28 (P<0.00001) |
−5.65 (−9.37, −1.93) I2=72%, Z=2.97 (P=0.003) |
−7.1 (−13.69, −0.52) I2=0, Z=2.11 (P=0.03) |
−244.40 (−279.97, −208.82) I2=93%, Z=13.46 (P<0.00001) |
−2.22 (−2.94, −1.49) I2=0, Z=6.02 (P<0.00001) |
Intervention effect ≥9 mo |
7 |
9166 |
−7.49 (−11.82, −3.17) I2=20%, Z=3.39 (P=0.0007) |
−11.57 (−18.65, −4.50) I2=0, Z=3.21 (P=0.001) |
−3.30 (−6.78, 0.18)*, Z=1.86 (P=0.06) |
−2.20 (−5.04, 0.64)*, Z=1.52 (P=0.13) |
−4.55 (−8.92, −0.18) I2=0, Z=2.04 (P=0.04) |
−18.30 (−49.32, 12.72)*, Z=1.16 (P=0.25) |
−310.37 (−350.24, −270.50) I2=88%, Z=15.26 (P<0.00001) |
−2.49 (−3.22, −1.77) I2=0, Z=6.75 (P<0.00001) |
Dosage of ARNI |
Medium/high dose ≤50% |
7 |
386 |
−18 (−31.89, −4.11)*, Z=2.54 (P=0.01) |
−21.68 (−24.46, −18.91), I2=50%, Z=15.31 (P<0.00001) |
NR |
−2.41 (−3.24, −1.58) I2=0, Z=5.71 (P<0.00001) |
NR |
NR |
−691 (−892.88, −489.12)*, Z=6.71 (P<0.00001) |
NR |
Medium/high dose >50% |
11 |
9671 |
−7.93 (−12.15, −3.7) I2=0, Z=3.68 (P=0.0002) |
−11.8 (−18.53, −5.06) I2=0, Z=3.43 (P=0.0006) |
−3.36 (−5.69, −1.03) I2=0, Z=2.82 (P=0.005) |
−2.47 (−3.52, −1.43) I2=0, Z=4.65 (P<0.00001) |
−5.81 (−10.51, −1.11) I2=0, Z=2.43 (P=0.02) |
−6.75 (−10.6, −2.89), I2=61%, Z=3.43 (P=0.0006) |
−308.8 (−349.28, −268.32) I2=85%, Z=14.95 (P<0.00001) |
−2.47 (−3.2, −1.75) I2=0, Z=6.67 (P<0.00001) |
Mean baseline SBP |
SBP ≤120 mm Hg |
4 |
423 |
−18.11 (−35.49, −0.72) I2=0, Z=2.04 (P=0.04) |
−20.66 (−40.97, −0.34), I2=0, Z=1.99 (P=0.05) |
−3.36 (−5.69, −1.03) I2=0, Z=2.82 (P=0.005) |
−2.54 (−3.96, −1.12) I2=0, Z=3.50 (P=0.0005) |
−14.44 (−22.61, −6.27)*, Z=3.46 (P=0.0005) |
−18.30 (−49.32, 12.72)*, Z=1.16 (P=0.25) |
NR |
NR |
SBP >120 mm Hg |
8 |
9324 |
−7.93 (−12.17, −3.7) I2=55%, Z=3.67 (P=0.0002) |
−20.31 (−22.91, −17.71), I2=79%, Z=15.3 (P<0.00001) |
NR |
−2.36 (−3.2, −1.52) I2=20%, Z=5.51 (P<0.00001) |
−4.55 (−8.92, −0.18) I2=0, Z=2.04 (P=0.04) |
−4.6 (−10.91, 1.71)*, Z=1.43 (P=0.15) |
−321.46 (−361.22, −281.71) I2=90%, Z=15.85 (P<0.00001) |
−2.46 (−3.19, −1.74) I2=0, Z=6.64 (P<0.00001) |
Different control groups |
ACEIs |
2 |
8649 |
NR |
−22 (−24.81, −19.19)*, Z=15.34 (P<0.00001) |
NR |
−3 (−4.4, −1.6)*, Z=4.21 (P<0.0001) |
NR |
NR |
−479.3 (−574.02, −384.58)*, Z=9.92 (P<0.00001) |
−2.5 (−3.24, −1.76)*, Z=6.66 (P<0.00001) |
ARBs |
3 |
533 |
−7.49 (−11.82, −3.17) I2=20%, Z=3.39 (P=0.0007) |
−11.57 (−18.65, −4.5), I2=0, Z=3.21 (P=0.001) |
−3.30 (−6.78, 0.18)*, Z=1.86 (P=0.06) |
−2.20 (−5.04, 0.64)*, Z=1.52 (P=0.13) |
−4.55 (−8.92, −0.18) I2=0, Z=2.04 (P=0.04) |
−5.14 (−11.33, 1.04), I2=0, Z=1.63 (P=0.1) |
−267 (−311.9, −222.1)*, Z=11.66 (P<0.00001) |
−0.8 (−5.86, 4.26)*, Z=0.31 (P=0.76) |
Etiology |
Ischemic heart disease ≤50% |
6 |
310 |
−18.11 (−35.49, −0.72) I2=0, Z=2.04 (P=0.04) |
−20.66 (−40.97, −0.34), I2=0, Z=1.99 (P=0.05) |
−3.36 (−5.69, −1.03) I2=0, Z=2.82 (P=0.005) |
−2.66 (−4.02, −1.29) I2=0, Z=3.82 (P=0.0001) |
NR |
−18.30 (−49.32, 12.72)*, Z=1.16 (P=0.25) |
−977.7 (−2324.81, 369.41)*, Z=1.42 (P=0.15) |
NR |
Ischemic heart disease >50% |
8 |
9194 |
−17.47 (−29.12, −5.82) I2=0, Z=2.94 (P=0.003) |
−21.58 (−24.34, −18.83), I2=16%,Z=15.34 (P<0.00001) |
NR |
−2.36 (−3.17, −1.55) I2=0, Z=5.72 (P<0.00001) |
NR |
−6.72 (−13.94, 0.5)*, Z=1.82 (P=0.07) |
−517.5 (−603.25, −431.74) I2=71%, Z=11.83 (P<0.00001) |
NR |
Concomitant therapy |
MRA ≤50% |
3 |
484 |
−7.49 (−11.82, −3.17) I2=20%, Z=3.39 (P=0.0007) |
−3.30 (−6.78, 0.18)*, Z=1.86 (P=0.06) |
|
−2.20 (−5.04, 0.64)*, Z=1.52 (P=0.13) |
−2.8 (−8.61, 3.01)*, Z=0.94 (P=0.35) |
−5.14 (−11.33, 1.04), I2=0, Z=1.63 (P=0.1) |
−267 (−311.9, −222.1)*, Z=11.66 (P<0.00001) |
−0.8 (−5.86, 4.26)*, Z=0.31 (P=0.76) |
MRA >50% |
12 |
9341 |
−18.4 (−28.74, −8.05) I2=0, Z=3.48 (P=0.0005) |
−21.59 (−24.33, −18.85), I2=0, Z=15.43 (P<0.00001) |
−3.60 (−6.16, −1.05) I2=0, Z=2.77 (P=0.006) |
−2.43 (−3.09, −1.78) I2=0, Z=7.28 (P<0.00001) |
−9.85 (−15.01, −4.7) I2=50%, Z=3.75 (P=0.0002) |
−7.1 (−13.69, −0.52) I2=0, Z=2.11 (P=0.03) |
−513.66 (−592.64, −434.67) I2=33%, Z=12.75 (P<0.00001) |
−2.54 (−3.27, −1.81) I2=0, Z=6.8 (P<0.00001) |